Mupirocin
Active ingredient · 2 therapeutic classes
Sold as STRAMUCIN
- Drug class
- Other Antibiotics For Topical Use
- Availability
- Prescription only
- Routes
- Topical
- Markets covered
- 3
- Products on record
- 27
- FDA reports (12 mo)
- 1,113
Overview
Plain-language summary, compiled from the cited regulatory records
Mupirocin is an antibiotic used topically [1]. It belongs to the drug class of other antibiotics for topical use [1].
Mupirocin cream is approved for treating secondarily infected traumatic skin lesions. These lesions should be up to 10 cm in length or 100 cm² in area and caused by susceptible strains of *Staphylococcus aureus* and *Streptococcus pyogenes* [1]. Mupirocin works by inhibiting RNA synthetase [1].
In the past 12 months, there have been 1113 adverse event reports associated with mupirocin [2]. The most frequent reactions reported include product use in an unapproved indication, drug ineffectiveness, off-label use, nausea, and pruritus [2].
This is not medical advice. Consult a qualified healthcare professional.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 23 | May 22, 2026 |
| US United States | FDA | 2 | March 18, 2025 |
| CA Canada | Health Canada | 2 | March 22, 2025 |
GBUnited Kingdom· MHRA
23 products
Uses
The elimination of nasal carriage of staphylococci, including methicillin resistant Staphylococcus aureus (MRSA)
How to take
USUnited States· FDA
2 products
Uses
1 INDICATIONS AND USAGE Mupirocin cream is indicated for the treatment of secondarily infected traumatic skin lesions (up to 10 cm in length or 100 cm 2 in area) due to susceptible isolates of Staphylococcus aureus (S. aureus) and Streptococcus pyogenes (S.
pyogenes) . Mupirocin cream is an RNA synthetase inhibitor antibacterial indicated for the treatment of secondarily infected traumatic skin lesions (up to 10 cm in length or 100 cm 2 in area) due to susceptible isolates of Staphylococcus aureus and Streptococcus pyogenes .
( 1 )
How to take
CACanada· Health Canada
2 products
Uses
STRAMUCINTM (Mupirocin Cream USP 2% w/w as mupirocin calcium) is indicated topically for the treatment of secondarily infected traumatic lesions such as small lacerations, sutured wounds or abrasions. To reduce the development of drug-resistant bacteria and maintain the effectiveness of mupirocin cream and other antibacterial drugs, mupirocin cream should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria.
When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
1 Pediatrics Pediatrics (18 months – 16 years of age): Based on the data submitted and reviewed by Health Canada, the safety and efficacy of mupirocin 2% cream in pediatric patients have been established; therefore, Health Canada has authorized an indication for pediatric use.
Drug interactions
Known interactions involving Mupirocin. Select one for details. This list is informational and not a complete interaction checker.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]MHRA (UK) · PL000380347 · revised October 17, 2025
- [2]FDA DailyMed · 0580458d-7178-40… · revised March 18, 2025 [PDF]
- [3]Health Canada (DPD) · 02483459 · revised March 22, 2025
- [4]OpenFDA adverse-event reports (US), 12 months ending June 4, 2026.
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.